HCV quasispecies evolution during treatment with interferon alfa-2b and ribavirin in two children coinfected with HCV and HIV-1

Journal of Clinical Virology

Volumn 43, Issue 2, 2008, Pages 236-240

  Quesnel Vallières, Mathieu ^a,b   Lemay, Mireille ^a,b   Lapointe, Normand ^a,b   Martin, Steven R ^a,b   Soudeyns, Hugo ^a,b  

^a UNIVERSITY OF MONTREAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Coinfection; Hepatitis C virus; Interferon; Mother to child transmission; Pediatrics; Ribavirin

Indexed keywords

ALPHA2B INTERFERON; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; PEGINTERFERON ALPHA2B; RIBAVIRIN; STAVUDINE;

ADOLESCENT; AMPLICON; ARTICLE; CASE REPORT; CD4 LYMPHOCYTE COUNT; CLINICAL FEATURE; EVOLUTION; FLU LIKE SYNDROME; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN TISSUE; LABORATORY TEST; MALE; MIXED INFECTION; NUCLEOTIDE SEQUENCE; PATIENT MONITORING; PRIORITY JOURNAL; SCHOOL CHILD; SEROLOGY; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; UNINDEXED SEQUENCE; VERTICAL TRANSMISSION; VIRUS ISOLATION; VIRUS LOAD; VIRUS REPLICATION; VIRUS STRAIN; WEIGHT REDUCTION;

ADOLESCENT; ANTIVIRAL AGENTS; CHILD; DRUG THERAPY, COMBINATION; EVOLUTION, MOLECULAR; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HIV-1; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; INTERFERON ALFA-2B; MALE; RIBAVIRIN; TREATMENT OUTCOME;

EID: 50849109550     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2008.06.019     Document Type: Article

References (26)

1. Alter M.J. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 44 1 Suppl (2006) S6-S9
2. Tedaldi E.M., Baker R.K., Moorman A.C., Alzola C.F., Fuhrer J., McCabe R.E., et al. Influence of coinfection with hepatitis C virus on morbidity and mortality due to human immunodeficiency virus infection in the era of highly active antiretroviral therapy. Clin Infect Dis 36 (2003) 363-367
3. Shire N.J., Welge J.A., and Sherman K.E. Response rates to pegylated interferon and ribavirin in HCV/HIV coinfection: a research synthesis. J Viral Hepat 14 (2007) 239-248
4. Schuval S., Van Dyke R.B., Lindsey J.C., Palumbo P., Mofenson L.M., Oleske J.M., et al. Hepatitis C prevalence in children with perinatal human immunodeficiency virus infection enrolled in a long-term follow-up protocol. Arch Pediatr Adolesc Med 158 (2004) 1007-1013
5. Canobio S., Guilbert C.M., Troesch M., Samson J., Lemay M., Pelletier V.A., et al. Differing patterns of liver disease progression and hepatitis C virus (HCV) quasispecies evolution in children vertically coinfected with HCV and human immunodeficiency virus type 1. J Clin Microbiol 42 (2004) 4365-4369
6. Pollack H., Hou Z., Hughes A.L., and Borkowsky W. Perinatal transmission and viral evolution of hepatitis C virus quasispecies in infants coinfected with HIV. J Acquir Immune Defic Syndr 36 (2004) 890-899
7. England K., Thorne C., and Newell M.L. Vertically acquired paediatric coinfection with HIV and hepatitis C virus. Lancet Infect Dis 6 (2006) 83-90
8. Martell M., Esteban J.I., Quer J., Genesca J., Weiner A., Esteban R., et al. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J Virol 66 (1992) 3225-3229
9. Farci P., Strazzera R., Alter H.J., Farci S., Degioannis D., Coiana A., et al. Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome. Proc Natl Acad Sci USA 99 (2002) 3081-3086
10. Farci P., Quinti I., Farci S., Alter H.J., Strazzera R., Palomba E., et al. Evolution of hepatitis C viral quasispecies and hepatic injury in perinatally infected children followed prospectively. Proc Natl Acad Sci USA 103 (2006) 8475-8480
11. Di Martino V., Rufat P., Boyer N., Renard P., Degos F., Martinot-Peignoux M., et al. The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study. Hepatology 34 (2001) 1193-1199
12. Kowala-Piaskowska A., Stuzewski W., Figlerowicz M., and Mozer-Lisewska I. Early virological response in children with chronic hepatitis C treated with pegylated interferon and ribavirin. Infection 35 (2007) 175-179
13. Thompson J.D., Gibson T.J., Plewniak F., Jeanmougin F., and Higgins D.G. The ClustalX windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res 25 (1997) 4876-4882
14. Kumar S., Tamura K., Jakobsen I.B., and Nei M. MEGA2: molecular evolutionary genetics analysis software. Bioinformatics 17 (2001) 1244-1245
15. Nei M., and Gojobori T. Simple methods for estimating the numbers of synonymous and nonsynonymous nucleotide substitutions. Mol Biol Evol 3 (1986) 418-426
16. Sturmer M., Doerr H.W., Staszewski S., and Preiser W. Comparison of nine resistance interpretation systems for HIV-1 genotyping. Antivir Ther 8 (2003) 239-244
17. Landau A., Batisse D., Piketty C., and Kazatchkine M.D. Effect of interferon and ribavirin on HIV viral load. AIDS 14 (2000) 96-97
18. Sulkowski M.S. Viral hepatitis and HIV coinfection. J Hepatol 48 (2008) 353-367
19. Law M., Maruyama T., Lewis J., Giang E., Tarr A.W., Stamataki Z., et al. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med 14 (2008) 25-27
20. Manns M.P., Wedemeyer H., and Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut 55 (2006) 1350-1359
21. John M., Flexman J., and French M.A. Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease?. AIDS 12 (1998) 2289-2293
22. Ofotokun I., Smithson S.E., Lu C., Easley K.A., and Lennox J.L. Liver enzymes elevation and immune reconstitution among treatment-naïve HIV-infected patients instituting antiretroviral therapy. Am J Med Sci 334 (2007) 334-341
23. Danta M., Semmo N., Fabris P., Brown D., Pybus O.G., Sabin C.A., et al. Impact of HIV on host-virus interactions during early hepatitis C virus infection. J Infect Dis 197 (2008) 1558-1566
24. Lau J.Y., Tam R.C., Liang T.J., and Hong Z. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology 35 (2002) 1002-1009
25. Chung R.T., Andersen J., Volberding P., Robbins G.K., Liu T., Sherman K.E., et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 351 (2004) 451-459
26. Wohnsland A., Hofmann W.P., and Sarrazin C. Viral determinants of resistance to treatment in patients with hepatitis C. Clin Microbiol Rev 20 (2007) 23-38